Answers are grounded in this paper and cite their sources.
Case series shows resolution of diarrhea and weight loss in individuals with IBS-D, suggesting new treatment options.
Irritable bowel syndrome with diarrhea (IBS-D) is a common functional gastrointestinal disorder. It is primarily caused by increased intestinal transit. GLP-1 receptor agonists (GLP-1 RAs) are widely used for obesity and diabetes management. They have been shown to decrease intestinal motility as a side effect. We present a 67-year-old woman and a 23-year-old woman, both with long-standing, debilitating IBS-D. Both achieved a 22.7-kg weight loss with GLP-1 RA use. They also reported resolution of diarrhea and improved quality of life. This case series suggests potential therapeutic benefits of GLP-1 RA use in hypermotility associated with IBS-D.
No takes yet. Share an insight, caveat, or question.
Suárez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: